Results 231 to 240 of about 50,635 (295)

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

open access: yesBritish Journal of Haematology, Volume 208, Issue 6, Page 1993-2003, June 2026.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez   +18 more
wiley   +1 more source

Molecular and clinical characteristics of glioma patients with germline pathogenic mutations of Lynch syndrome genes: a large-scale multicenter study. [PDF]

open access: yesJ Transl Med
Feng J   +21 more
europepmc   +1 more source

Diagnostic accuracy of 1H-MRS in detecting the oncometabolite 2-hydroxyglutarate (2HG) in adult-type diffuse gliomas. [PDF]

open access: yesJ Neurooncol
Hebda A   +8 more
europepmc   +1 more source

Isocitrate dehydrogenase (IDH)

open access: yes, 2015
Frank Gaillard   +2 more
openaire   +1 more source

Prognostic Importance of Histomolecular Subtyping of Central Nervous System Gliomas in Low and Middle-Income Countries. [PDF]

open access: yesBrain Tumor Res Treat
Laghari AA   +7 more
europepmc   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

open access: yesJournal of Gastroenterology and Hepatology, Volume 41, Issue 6, Page 1701-1721, June 2026.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy